GLP-1 Drugs and Heart Failure: Benefit Seems to Depend on Obesity

GLP-1 drugs help the heart, but not in the same way for everyone

GLP-1 receptor agonists have earned their reputation as cardiovascular drugs. Across large randomized trials, they lower cardiovascular death and major adverse cardiovascular events. That part is solid. The messy part is heart failure. The best current evidence suggests these drugs do not reduce heart failure hospitalization across all patients. That benefit appears mainly in people with obesity, which points to a different mechanism than many headlines imply.

The key paper is a 2025 meta-analysis by Zhang et al. It pooled 18 randomized controlled trials with about 97,800 patients who had cardiovascular or renal disease. The authors found that GLP-1 receptor agonists reduced cardiovascular death, with a relative risk of 0.88 and a 95% confidence interval of 0.83 to 0.93, and also reduced major adverse cardiovascular events, again with a relative risk of 0.88 and a 95% confidence interval of 0.84 to 0.91. Those benefits held regardless of baseline BMI. Heart failure hospitalization was different. In the full pooled population, the relative risk was 0.92 with a 95% confidence interval of 0.78 to 1.08, which is not statistically significant.

Then the plot thickened. In the subgroup with obesity, defined as BMI 30 or higher, heart failure hospitalization fell significantly, and the interaction by BMI reached statistical significance with P = 0.02 in the same Zhang et al. analysis. That does not prove a clean biological cutoff at BMI 30. Trialists love round numbers almost as much as clinicians do. But it does suggest that adiposity does more than ride in the back seat.

Why obesity changes the heart failure story

This pattern makes sense if the benefit targets less the heart muscle itself and more the metabolic and mechanical burden wrapped around it. In obesity-related heart failure with preserved ejection fraction, or HFpEF, excess adiposity can drive disease through epicardial fat, plasma volume expansion, systemic inflammation, and altered myocardial fuel use. A 2025 systematic review by Hullon et al. lays out that model in detail and argues that GLP-1 receptor agonists may help by reducing epicardial adipose tissue, dampening adipose-linked inflammatory signaling, and improving diastolic function. That is a plausible mechanism. It is not direct proof, because the available evidence does not include within-trial biomarker data stratified by BMI for markers such as NT-proBNP, E/e', left ventricular mass, or epicardial fat volume.

That distinction matters. If the drug class acted as a broad heart failure therapy, you would expect a more uniform signal across body sizes and heart failure phenotypes. Instead, the evidence lines up best with the obesity-HFpEF phenotype. An updated 2025 meta-analysis by Duhan et al., restricted to patients with mildly reduced or preserved ejection fraction, found that GLP-1 receptor agonists improved functional outcomes and reduced heart failure hospitalization in HFmrEF and HFpEF populations. That supports benefit in the phenotype most tightly linked to visceral adiposity. It does not support a blanket claim for heart failure in general.

What semaglutide and tirzepatide add to the picture

The strongest trial-level support in obese patients comes from the 2024 SELECT prespecified analysis by Deanfield et al. In patients with obesity, prevalent heart failure, and no diabetes, semaglutide reduced major adverse cardiovascular events versus placebo. That matters because it strips away some of the usual diabetes confounding. The cardiovascular benefit in obese patients with heart failure does not depend on glucose lowering alone.

Tirzepatide raises an obvious follow-up question: if the heart failure benefit is mediated mainly by weight loss and obesity-linked biology, would the drug that produces more weight loss produce more heart failure benefit? Mechanistically, that is a reasonable bet. A 2025 Cochrane review of tirzepatide by Franco et al. reported about 20% to 22% body weight reduction in adults with obesity, while a 2025 Cochrane review of semaglutide by Bracchiglione et al. reported about 15% weight loss. More fat loss could mean more unloading of the obesity-HFpEF machinery.

There is also a useful clue from a 2025 prespecified SUMMIT analysis by Packer et al. In obese patients with HFpEF, type 2 diabetes attenuated the magnitude of tirzepatide-induced weight loss. That finding strengthens the case that weight loss itself, rather than glycemic control, mediates much of the benefit in this phenotype. But restraint beats enthusiasm here. SUMMIT enrolled obese HFpEF patients only. It had no non-obese comparator arm, so it cannot prove that obesity determines response. It shows benefit within one stratum, not the boundary between strata.

Why this is not a general heart failure drug class

The main reason is simple: the overall heart failure hospitalization result is null in the largest pooled analysis. If someone calls GLP-1 drugs "heart failure drugs" without qualification, they are skipping the hardest line in the paper.

The second reason is phenotype. Historical liraglutide data in heart failure with reduced ejection fraction, discussed in Hullon et al., showed neutral-to-adverse signals, and the more favorable meta-analytic results apply to HFmrEF and HFpEF rather than HFrEF in Duhan et al. If the dominant problem is neurohormonal HFrEF rather than obesity-driven congestion and inflammation, the biological target may simply be different.

The third reason is competition from a class that does reduce heart failure hospitalization across a broader spectrum. A 2023 meta-analysis by Sohn et al. found that SGLT2 inhibitors outperform GLP-1 receptor agonists on heart failure hospitalization in type 2 diabetes populations. That fits the mechanism. SGLT2 inhibitors act through natriuresis, hemodynamic unloading, and myocardial metabolic effects that do not depend on obesity to the same extent.

What the broader GLP-1 literature does and does not prove

If the question is cardiovascular death or major adverse cardiovascular events, the class effect looks consistent. A 2025 meta-analysis by Lee et al. found that long-acting injectable and oral GLP-1 receptor agonists improved cardiovascular and kidney outcomes in type 2 diabetes. That supports the idea that broad cardioprotection is real across formulations.

It does not settle the heart failure hospitalization question, because heart failure hospitalization was not the primary robust endpoint in most of that literature. The heart failure signal remains narrower, more conditional, and more vulnerable to subgroup noise than the MACE and mortality signals.

The caveats matter here

The obesity interaction from Zhang et al. comes from a pooled subgroup analysis, not from a single cardiovascular outcomes trial with heart failure hospitalization as a prespecified primary endpoint. A P value of 0.02 for interaction is interesting, but subgroup interactions can misbehave. The overall confidence interval for heart failure hospitalization is also wide enough to allow anything from modest benefit to no benefit at all in the full population.

There are other limits. Most of the cardiovascular outcomes trials enrolled patients with type 2 diabetes, which makes it hard to cleanly separate adiposity effects from glycemic effects. Individual BMI-stratified heart failure results from major trials were not available across the board, so it is unclear whether the interaction is consistent or driven by a few large studies. BMI itself is a blunt tool. It may stand in for visceral adiposity, epicardial fat, or disease stage. A patient with a BMI of 29 and a lot of visceral fat does not become biologically different because the scale missed by one point.

The current evidence supports a narrower claim than the marketing copy: GLP-1 drugs reduce cardiovascular death broadly, but their heart failure hospitalization benefit appears concentrated in patients whose heart failure is tied to obesity.

The practical read

If a patient has obesity, especially obesity-linked HFpEF, these drugs look more like true heart failure-relevant therapy and less like weight-loss drugs with a side hustle. Semaglutide has trial-level support in obese patients with prevalent heart failure in SELECT. Tirzepatide has the stronger weight-loss profile in Cochrane data and a plausible mechanistic edge, but no head-to-head cardiovascular outcomes trial has shown that it prevents more heart failure hospitalizations than semaglutide.

If the patient is non-obese, especially with HFrEF, the evidence does not support expecting heart failure hospitalization benefit from a GLP-1 drug. In that setting, SGLT2 inhibitors remain the cleaner evidence-based choice for heart failure prevention across the weight spectrum.

The most honest bottom line is this: GLP-1 drugs help the cardiovascular system in general, but their heart failure benefit appears conditional. They do not fix every failing heart. They seem to work best when fat is part of what is breaking it.